

Received:
02 August 2020

Revised:
25 September 2020

Accepted:
28 September 2020

<https://doi.org/10.1259/bjr.20200934>

Cite this article as:

Giganti F, Allen C. Imaging quality and prostate MR: it is time to improve. *Br J Radiol* 2020; **94**: 20200934.

COMMENTARY

Imaging quality and prostate MR: it is time to improve

^{1,2}FRANCESCO GIGANTI and ¹CLARE ALLEN

¹Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK

²Division of Surgery & Interventional Science, University College London, London, UK

Address correspondence to: Dr Francesco Giganti

E-mail: f.giganti@ucl.ac.uk

ABSTRACT

The Prostate Imaging Reporting and Data System (PI-RADS) guidelines set out the minimal technical requirements for the acquisition of multiparametric MRI (mpMRI) of the prostate. However, the rapid diffusion of this technique has inevitably led to variability in scan quality among centres across the UK and the world. Suboptimal image acquisition reduces the sensitivity and specificity of this technique for the detection of clinically significant prostate cancer and results in clinicians losing confidence in the technique.

Two expert panels, one from the UK and one from the European Society of Urogenital Radiology (ESUR)/EAU Section of Urologic Imaging (ESUI), have stressed the importance to establish quality criteria for the acquisition of mpMRI of the prostate. A first attempt to address this issue has been the publication of the Prostate Imaging Quality (PI-QUAL) score, which assesses the mpMRI quality against a set of objective criteria (PI-RADS guidelines) together with criteria obtained from the image.

PI-QUAL represents the first step towards the standardisation of a scoring system to assess the quality of prostate mpMRI prior to reporting and allows clinicians to have more confidence in using the scan to determine patient care. Further refinements after robust consensus among experts at an international level need to be agreed before its widespread adoption in the clinical setting.

INTRODUCTION

There has been a steep increase in the use of multiparametric MRI (mpMRI) of the prostate over the last decade and this has resulted in high variability of scan quality and reporting.¹

High-quality MR images of the prostate are a key determinant in an MRI-led prostate cancer diagnostic pathway. MRI-derived targeted biopsies are used to detect clinically significant prostate cancer and a negative scan can be used to safely avoid unnecessary immediate biopsy.²

It is impossible to provide a tailored mpMRI prostate imaging protocol for every MR system due to the number of different vendors and the different ages of the scanners available. There will also be some variability due to patient factors such as movement and rectal gas.

For either detection or exclusion of prostate cancer, images with good spatial resolution and high signal-to-noise ratio for each sequence [T_2 -weighted imaging (T2-WI), diffusion-weighted imaging (DWI) and dynamic contrast enhanced (DCE) sequences] are needed.

The first attempt to overcome this issue was the publication of the Prostate Imaging Reporting and Data System (PI-RADS) guidelines v.1 in 2012, which outlined the minimum technical requirements and standards for prostate mpMRI reporting.³

Following the increasing body of evidence gained from their widespread application, the PI-RADS guidelines were subsequently refined in 2015 (v. 2.0) and in 2019 (v. 2.1).^{4,5}

The most recent technical requirements for a good quality prostate mpMRI according to PI-RADS v.2.1 guidelines are presented in [Table 1](#).

Where are we?

There is growing evidence that a formal assessment of prostate MRI quality is needed and interesting results from different institutions across the world have been published.⁶⁻¹⁰

A UK consensus meeting has stressed the importance of ensuring high-quality MR acquisition and reporting, especially if prostate mpMRI is used as a means of avoiding biopsy.¹¹

Table 1. Minimal technical requirements for multiparametric prostate MRI according to the PI-RADS v. 2.1 guidelines

	T₂-weighted imaging (T2-WI)	Diffusion-weighted imaging (DWI)	Dynamic contrast enhanced (DCE)
Imaging planes	Same used for DWI and DCE	Same used for T2-WI and DCE	Same used for T2-WI and DWI
Slice thickness	3 mm, no gap	≤ 4 mm, no gap	3 mm, no gap
Field of view	12 – 20 cm ^a	16 – 22 cm	12 – 20 cm ^a
In-plane dimension	≤ 0.7 mm (phase) × ≤ 0.4 mm (frequency)	≤ 2.5 mm (phase and frequency)	≤ 2 mm (phase and frequency)
Specific recommendations			
T2-WI acquisition	Axial plane: either straight axial to the patient or in an oblique axial plane matching the long axis of the prostate	-	-
	At least one additional orthogonal plane (sagittal and/or coronal)	-	-
	3D axial as an adjunct to 2D acquisitions	-	-
Low b value	-	0 (preferably 50)–100 s/mm ²	-
Intermediate b value	-	800 – 1000 s/mm ²	-
High b value	-	<ul style="list-style-type: none"> • Dedicated (≥ 1,400 s/mm²) • Synthesised (from other b-values) 	-
Temporal resolution	-	-	≤ 15 s
Total observation rate	-	-	> 2 min
Dose of GBCA	-	-	0.1 mmol/kg
Injection rate	-	-	2 – 3 cc/s
Fat suppression/subtraction	-	-	Recommended

DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; GBCA, Gadolinium-based contrast agent; T2-WI, T₂-weighted imaging.

<https://www.acr.org/-/media/ACR/Files/RADS/PI-RADS/PIRADS-V2-1.pdf>

^a to encompass the entire prostate gland and seminal vesicles

In addition to this, a recent statement from the European Society of Urogenital Radiology (ESUR) and the EAU Section of Urologic Imaging (ESUI) has shown that there is still huge variability in the conduct of prostate mpMRI and has also highlighted the need to define requirements for learning and accumulation of reporting experience for mpMRI.^{12,13}

The ESUR/ESUI consensus paper includes a summary of the opinions of recognised experts in diagnostic prostate MRI following a Delphi consensus process on quality measures that are not adequately addressed by current literature, but a set of objective criteria for assessing image quality has not been provided.¹²

A first attempt to fill this gap is represented by the recent publication of a dedicated scoring system from the multicentre randomised PRECISION trial,² called Prostate Imaging Quality (PI-QUAL).¹⁴

The PI-QUAL score is based on a 1-to-5 Likert scale derived by evaluating each mpMRI sequence (T2-WI, DWI and DCE) against a defined set of objective quality criteria in line with PI-RADS v.2 guidelines⁴ and using a subjective assessment of the image (Table 2). A poor-quality scan should not be used for a diagnostic assessment of the prostate.

There can be significant variability in the acquisition of prostate mpMRI and often adherence to the PI-RADS guidelines does not necessarily lead to a diagnostic quality image. For example, although the apparent diffusion coefficient (ADC) values have been reported to correlate inversely with adverse histology in prostate cancer, there is still considerable overlap between benign prostatic hyperplasia, low-grade and high-grade tumours. Although the PI-RADS v. 2.1 guidelines suggest a threshold of 750–900 μm²/s to differentiate between benign and malignant prostate tissue, ADC calculations are influenced by the choice of b-values and cannot be standardised due to the inconsistency across vendors. It has been shown that the use of a ratio (ADC ratio) of prostate tumour ADC to normal tissue ADC or to the ADC of the urine in the bladder on a single scanner can provide a more robust means of assessing restricted diffusion in the prostate.^{15–18} However, visual assessment is often used as the primary method to assess the quality of DWI.

Other factors related to the patient (*e.g.*, patient motion, patient size, or the degree of rectal distension) or dependent on the expertise of the radiographer acquiring the MR study could heavily impact on the quality of prostate mpMRI.

In addition to this, the scans from non-specialist centres usually show poorer imaging quality due to a lack of insight into the

Table 2. Assessment of the diagnostic quality of multiparametric MRI scans using the PI-QUAL score

PI-QUAL score	Criteria	Clinical Implications
1	All mpMRI sequences are below the minimum standard for diagnostic quality	It is NOT possible to rule in all significant lesions ^a
2	Only one mpMRI sequence is of acceptable diagnostic quality	It is NOT possible to rule out all significant lesions ^a
3	At least two mpMRI sequences taken together are of acceptable diagnostic quality	It is possible to rule in all significant lesions It is NOT possible to rule out all significant lesions
4	Two or more mpMRI sequences are independently of optimal diagnostic quality	It is possible to rule in all significant lesions
5	All mpMRI sequences are of optimal diagnostic quality	It is possible to rule out all significant lesions

PI-QUAL, Prostate Imaging Quality; PI-RADS, Prostate Imaging Reporting and Data System; mpMRI, multiparametric magnetic resonance imaging. Reprinted from Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V, for the PRECISION study group. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the prostate from the PRECISION trial. *Eur Urol Oncol*; 3(5):615-619. doi: 10.1016/j.euo.2020.06.007. Copyright (2020), with permission from Elsevier (<https://euoncology.europeanurology.com>).

^a Therefore reports should not include PI-RADS or Likert scores.

problem and lack of awareness of the quality achieved in high-volume, academic centres. Therefore, PI-QUAL represents the first effort to inform the radiological community of the importance of prostate MR quality and its widespread adoption could help to drive improvements when the imaging quality is inadequate.¹⁹

We also know that the negative predictive value of mpMRI is far higher than the positive predictive value (e.g. using a threshold of PI-RADS ≥ 3), which means that mpMRI is better as a 'rule-out' (i.e. biopsies can be avoided) rather than as a 'rule-in' (i.e. biopsy required to confirm cancer, as imaging alone insufficient) test.²⁰ Therefore, with a PI-QUAL score of 3 (i.e. the examination is of sufficient diagnostic quality) but high clinical suspicion (e.g. family history of prostate cancer or high PSA density), a systematic biopsy cannot be confidently avoided, as although the quality of the scan is acceptable, the negative predictive value may be compromised.²¹ It should be also mentioned that a large conspicuous lesion may still be apparent on suboptimal quality imaging (e.g. PI-QUAL 2) and could therefore still be called despite the poor image quality, but any small lesion will be inevitably missed at the same time.

What's next?

During the quality assurance work in PRECISION that led to the publication of PI-QUAL,¹⁴ the highest variability in quality of mpMRI was for DCE sequences, followed by DWI and T2-WI. This may explain why some centres have been able to drop the DCE sequences with no effect on their ability to diagnose significant prostate cancer. It should be stressed that PI-QUAL has been conceived for mpMRI and assumes that all three sequences (T2-WI, DWI and DCE) have been acquired. Therefore, PI-QUAL cannot be applied on biparametric MRI and this will be definitely taken into account in PI-QUAL v. 2, especially since a recent study has shown that 44% of MRI studies in the UK are performed without contrast.²²

Scanner age is also a significant factor that influences the quality of prostate mpMRI. This requires more investigation but from our preliminary work and our experience MR scanners over 10 years old are not able to produce diagnostic quality studies. In addition

to this, Burn and colleagues have shown a significant difference in prostate MR quality at a 7-year cut-off for scanner age.⁶

Adherence to the minimum acceptable technical parameters of mpMRI as outlined in the PI-RADS v. 2.1 guidelines⁵ is a good starting point to improve the quality of prostate MR; however, this is just a guide and the quality can also be improved using newer fat-saturation techniques, parallel imaging and motion reduction techniques. Often the sequences that are preloaded by the MR vendor are not of sufficient quality for prostate imaging and it is important to work with MR radiographers and physicists until a diagnostic set of sequences is obtained.

Therefore, it is important that the quality is high both at a 'centre level' (i.e. a centre should produce good quality prostate MRI with up-to-date MR scanners and dedicated radiologists/radiographers highly experienced in prostate MRI) and at a 'patient level' (i.e. patient-related artefacts such as rectal gas or movement should be minimised).

Some of the current technical standards set out in PI-RADS v. 2.1 guidelines⁵ could warrant reconsideration. For example, PI-RADS v. 2.1 technical recommendations mainly focus on spatial and temporal resolution but there is no mention of contrast resolution and other scan parameters. This should be addressed in the future, especially since the widespread adoption of mpMRI as a first-line investigation in patients with suspected prostate cancer.

Further research on what is most important in these technical guidelines and perhaps the formation of a sequence bank for sharing best practice to improve mpMRI quality along with the use of automated methods (including those based on deep learning) is advocated.¹⁹

In conclusion, the first version of PI-QUAL (v. 1) represents the start of identifying a framework for the assessment of prostate MR quality. It will give clinicians confidence to act on

the scan findings and help to reduce scan variability. It is the basis for future works and will require further refinement and prospective validation.

FUNDING

Francesco Giganti is funded by the UCL Graduate Research Scholarship and the Brahm PhD scholarship in memory of Chris Adams.

REFERENCES

- Giganti F, Rosenkrantz AB, Villeirs G, Panebianco V, Stabile A, Emberton M, et al. The evolution of MRI of the prostate: the past, the present, and the future. *AJR Am J Roentgenol* 2019; **213**: 384–96. doi: <https://doi.org/10.2214/AJR.18.20796>
- Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-Targeted or standard biopsy for prostate-cancer diagnosis. *N Engl J Med* 2018; **378**: 1767–77. doi: <https://doi.org/10.1056/NEJMoa1801993>
- Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. *Eur Radiol* 2012; **22**: 746–57. doi: <https://doi.org/10.1007/s00330-011-2377-y>
- Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. *Eur Urol* 2016; **69**: 16–40. doi: <https://doi.org/10.1016/j.eururo.2015.08.052>
- Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. *Eur Urol* 2019; **76**: 340–51. doi: <https://doi.org/10.1016/j.eururo.2019.02.033>
- Burn PR, Freeman SJ, Andreou A, Burns-Cox N, Persad R, Barrett T. A multicentre assessment of prostate MRI quality and compliance with UK and international standards. *Clin Radiol* 2019; **74**: 894.e19–894.e25. doi: <https://doi.org/10.1016/j.crad.2019.03.026>
- Sackett J, Shih JH, Reese SE, Brender JR, Harmon SA, Barrett T, et al. Quality of prostate MRI: is the PI-RADS standard sufficient? *Acad Radiol* 2020; **S1076(6332(20))**: 30080–5. doi: <https://doi.org/10.1016/j.acra.2020.01.031>
- Esses SJ, Taneja SS, Rosenkrantz AB. Imaging facilities' adherence to PI-RADS V2 minimum technical standards for the performance of prostate MRI. *Acad Radiol* 2018; **25**: 188–95. doi: <https://doi.org/10.1016/j.acra.2017.08.013>
- Jambor I. Optimization of prostate MRI acquisition and post-processing protocol: a pictorial review with access to acquisition protocols. *Acta Radiol Open* 2017; **6**: 205846011774557. doi: <https://doi.org/10.1177/2058460117745574>
- Coşkun M, Sarp AF, Karasu Şebnem, Gelal MF, Türkbey B. Assessment of the compliance with minimum acceptable technical parameters proposed by PI-RADS V2 guidelines in multiparametric prostate MRI acquisition in tertiary referral hospitals in the Republic of Turkey. *Diagn Interv Radiol* 2019; **25**: 421–7. doi: <https://doi.org/10.5152/dir.2019.18537>
- Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, et al. National implementation of multiparametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. *BJU Int* 2018; **122**: 13–25. doi: <https://doi.org/10.1111/bju.14361>
- de Rooij M, Israël B, Barrett T, Giganti F, Padhani AR, Panebianco V, Tummers M, et al. Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training. *Eur Urol* 2020; **78**: 483–5. doi: <https://doi.org/10.1016/j.eururo.2020.06.023>
- de Rooij M, Israël B, Tummers M, Ahmed HU, Barrett T, Giganti F, et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training. *Eur Radiol* 2020; **30**: 5404–16. doi: <https://doi.org/10.1007/s00330-020-06929-z>
- Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V. Prostate imaging quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the precision trial. *Eur Urol Oncol* 2020 **9311**: 30085–752588. doi: <https://doi.org/10.1016/j.euo.2020.06.007>
- Barrett T, Priest AN, Lawrence EM, Goldman DA, Warren AY, Gnanapragasam VJ, et al. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. *AJR Am J Roentgenol* 2015; **205**: W585–93. doi: <https://doi.org/10.2214/AJR.15.14338>
- Bajgiran AM, Mirak SA, Sung K, Sisk AE, Reiter RE, Raman SS. Apparent diffusion coefficient (ADC) ratio versus conventional ADC for detecting clinically significant prostate cancer with 3-T MRI. *AJR Am J Roentgenol* 2019; **213**: W134–42. doi: <https://doi.org/10.2214/AJR.19.21365>
- Schieda N, Lim CS, Zabihollahy F, Abreu-Gomez J, Krishna S, Woo S, et al. Quantitative prostate MRI. *J Magn Reson Imaging* 2020; doi: <https://doi.org/10.1002/jmri.27191>
- Giganti F, Pecoraro M, Fierro D, Campa R, Del Giudice F, Punwani S, et al. DWI and PRECISE criteria in men on active surveillance for prostate cancer: a multicentre preliminary experience of different ADC calculations. *Magn Reson Imaging* 2020; **67**: 50–8. doi: <https://doi.org/10.1016/j.mri.2019.12.007>
- Turkbey B, Choyke PL. PI-QUAL, a new system for evaluating prostate magnetic resonance imaging quality: is beauty in the eye of the beholder? *Eur Urol Oncol* 2020; **3**: 620–1. doi: <https://doi.org/10.1016/j.euo.2020.07.003>
- Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, et al. Negative multiparametric magnetic resonance imaging for prostate cancer: what's next? *Eur Urol* 2018; **74**: 48–54. doi: <https://doi.org/10.1016/j.eururo.2018.03.007>
- Giannarini G, Valotto C, Girometti R, Dal Moro F, Briganti A, Padhani AR. Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologist's Perspective. *Eur Urol* 2020; **S0302-2838**: 30707-7. doi: <https://doi.org/10.1016/j.eururo.2020.09.015>
- Davies C, Castle JT, Stalbow K, Haslam PJ. Prostate mpMRI in the UK: the state of the nation. *Clin Radiol* 2019; **74**: 894.e11–894.e18. doi: <https://doi.org/10.1016/j.crad.2019.09.129>